Messenger RNA (mRNA) vaccine technology gained widespread attention during the COVID-19 pandemic, revolutionizing the way vaccines are developed and deployed. Since their introduction, mRNA vaccines have not only played a critical role in controlling the pandemic but also opened new possibilities for fighting other infectious diseases and even cancer. Understanding how mRNA vaccines work, their safety profile, and their potential applications helps clarify their importance and addresses some common misconceptions.
Traditional vaccines typically work by introducing a weakened or inactivated version of a virus or bacterium-or a specific protein from a pathogen's surface-into the body. This exposure trains the immune system to recognize and respond to the pathogen without causing the full-blown disease. If the body encounters the actual pathogen later, it is better prepared to fight it off quickly.
mRNA vaccines, however, use a different approach. Instead of injecting a pathogen or protein directly, these vaccines provide the body with a snippet of messenger RNA, or mRNA, which is genetic material copied from the pathogen's DNA that encodes one of its proteins. Once inside the body's cells, this mRNA acts as a set of instructions, prompting the cells to produce the pathogen protein themselves. The immune system then recognizes this protein and mounts a defense against it, preparing the body for future encounters with the actual pathogen.
One common concern about mRNA vaccines is whether they can alter a person's DNA. Experts have repeatedly clarified that this is not possible. The mRNA introduced by the vaccine does not enter the cell nucleus, which houses the body's DNA. Instead, it remains in the cell's cytoplasm and is rapidly broken down after instructing the cell to make the protein. Additionally, mRNA is a molecule that humans routinely ingest through food, and it is naturally degraded by the body's digestive system and cellular mechanisms. To protect the mRNA until it reaches the cells, vaccine developers encase it in lipid nanoparticles-tiny fatty molecules that form a protective bubble, enabling efficient delivery into cells and preventing premature breakdown.
Like all vaccines, mRNA vaccines also contain other ingredients such as salts, sugars, acids, and stabilizers that help maintain their shelf life and allow for freezing during storage and transportation.
Historically, vaccines have fallen into three broad categories: whole-virus vaccines, subunit vaccines, and mRNA vaccines.
Whole-virus vaccines use either inactivated pathogens, like many polio vaccines, or live but weakened versions of viruses, such as those used for measles, mumps, and rubella (MMR). These vaccines closely mimic the actual pathogen, which helps the immune system mount a strong and specific response. However, they sometimes cause stronger side effects and, in rare cases, live weakened viruses can regain infectious capabilities.
Subunit vaccines contain only specific parts of a pathogen, usually proteins. These are safer because they carry no risk of causing infection. However, they may require additional substances called adjuvants to enhance the immune response. Examples include vaccines for respiratory syncytial virus (RSV), pneumococcal infections, whooping cough, hepatitis B, tetanus, and human papillomavirus (HPV).
mRNA vaccines represent a newer category, which delivers genetic instructions for producing a pathogen protein rather than the protein itself or the entire pathogen. This innovation allows the body to produce the protein internally, stimulating the immune system to recognize the threat.
While mRNA vaccines have demonstrated remarkable efficacy, they can cause side effects, known scientifically as reactogenicity. During the rollout of COVID-19 mRNA vaccines, more than half of recipients reported symptoms like pain at the injection site, fever, and headaches. These side effects, although unpleasant, are generally short-lived and far less severe than symptoms caused by actual infection. Interestingly, some evidence suggests that experiencing more side effects may correlate with a stronger immune response.
A rare but notable side effect observed with COVID-19 mRNA vaccines is myocarditis-inflammation of the heart muscle-primarily occurring in male teenagers and young adults. This condition typically develops within a few days of vaccination and affects approximately one in every 140,000 first-dose recipients. Importantly, myocarditis can also result from COVID-19 infection itself, with infection-associated heart complications being more frequent and severe than vaccine-related cases.
One limitation of the COVID-19 mRNA vaccines is that the protection they offer against infection tends to wane relatively quickly. This appears linked to a lower production of immune memory cells compared to other vaccine types. The reasons behind this phenomenon remain unclear, despite the vaccines' ability to generate a robust initial immune response.
One of the greatest strengths of mRNA vaccine technology is the speed at which vaccines can be developed and updated. During the early stages of the COVID-19 pandemic, this rapid development was crucial, enabling vaccines to be ready when the virus was spreading through an unprotected population. This speed was partly due to prior research on similar viruses, which allowed scientists to design mRNA vaccines quickly for SARS-CoV-2.
As the virus has evolved, mRNA vaccines have also been updated to better match emerging variants. This adaptability showcases the technology's flexibility, making mRNA vaccines particularly valuable during pandemics or outbreaks when rapid response is essential.
Beyond COVID-19, mRNA vaccines hold promise for improving seasonal influenza vaccines. Currently, flu vaccines are developed months in advance based on predictions about which strains will dominate the upcoming season. This forward planning can leave populations vulnerable if new strains emerge too late to be included in the vaccine formulation. For example, a dominant flu variant called subclade K emerged late in a recent flu season, contributing to high infection rates because it was not covered by the vaccine. The mRNA platform's quick adaptability could allow for more timely updates to flu vaccines, potentially improving their effectiveness.
Researchers are also exploring mRNA vaccines to target challenging pathogens like HIV and dengue, diseases for which vaccine development has historically been difficult. Moreover, the technology is already being applied to cancer treatments, where mRNA vaccines help stimulate the immune system to recognize and attack cancer cells.
Despite some political and administrative resistance to mRNA vaccine technology-including initial reluctance by the Food and Drug Administration (FDA) to review an mRNA influenza vaccine and budget cuts to mRNA research-many scientists remain optimistic about the technology's future. They view mRNA vaccines as a versatile, powerful tool for addressing infectious diseases, improving cancer therapy, and potentially preventing future pandemics.
The COVID-19 pandemic has demonstrated the life-saving potential of mRNA vaccines, which prevented an estimated eight million infections within the first six months of use. As research continues and the technology matures, mRNA vaccines are expected to play a growing role in public health worldwide.
In sum, mRNA vaccine technology represents a major advance in vaccinology, offering rapid development, adaptability, and strong immune protection. While side effects exist, they are generally mild and far outweighed by the benefits of vaccination. Ongoing research and development will likely expand the use of mRNA vaccines beyond COVID-19, addressing other infectious diseases and cancers, and reshaping the future of medicine.
---
Meghan Bartels is a senior science reporter at Scientific American, based in New York City. She has written extensively about space, Earth science, and medical research. This article reflects her commitment to clear, accurate science communication.